Neophytou C, Boutsikos P, Papageorgis P. Molecular mechanisms and emerging therapeutic targets of triple-negative breast cancer metastasis. Front Oncol. 2018;8:31.

Article  PubMed  PubMed Central  Google Scholar 

Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9:S73–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol. 2021;72:136–45.

Article  CAS  PubMed  Google Scholar 

Petrucelli N, Daly MB, Pal T, BRCA1-and BRCA2-associated hereditary breast and ovarian cancer. 2022

Vishnubalaji R, Alajez NM. Single-cell transcriptome analysis revealed heterogeneity and identified novel therapeutic targets for breast cancer subtypes. Cells. 2023;12:1182.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akhouayri L, Ostano P, Mello-Grand M, Gregnanin I, Crivelli F, Laurora S, et al. Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles. Hum Genomics. 2022;16:1–17.

Article  Google Scholar 

Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE. 2016;11: e0157368.

Article  PubMed  PubMed Central  Google Scholar 

Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19:5533–40.

Article  CAS  PubMed  Google Scholar 

Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688–98.

Article  CAS  PubMed  Google Scholar 

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig. 2011;121:2750–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu K-D, Zhu R, Zhan M, Rodriguez AA, Yang W, Wong S, et al. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res. 2013;19:2723–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:1–18.

Article  Google Scholar 

Staiger C, Cadot S, Györffy B, Wessels LF, Klau GW. Current composite-feature classification methods do not outperform simple single-genes classifiers in breast cancer prognosis. Front Genet. 2013;4:289.

Article  PubMed  PubMed Central  Google Scholar 

Xu Y, Xu Q, Yang L, Ye X, Liu F, Wu F, et al. Identification and validation of a blood-based 18-gene expression signature in colorectal cancer. Clin Cancer Res. 2013;19:3039–49.

Article  CAS  PubMed  Google Scholar 

Sabatier R, Diéras V, Pivot X, Brain E, Roche H, Extra J-M, et al. Safety results and analysis of eribulin efficacy according to previous microtubules-inhibitors sensitivity in the French prospective expanded access program for heavily pre-treated metastatic breast cancer. Cancer Res Treat. 2018;50:1226–37.

Article  PubMed  Google Scholar 

Watanabe G, Chiba N, Nomizu T, Furuta A, Sato K, Miyashita M, et al. Increased centrosome number in BRCA-related breast cancer specimens determined by immunofluorescence analysis. Cancer Sci. 2018;109:2027–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang SY, Kim YS, Kim Z, Kim HY, Kim HJ, Park S, et al. Breast cancer statistics in Korea in 2017: data from a breast cancer registry. J Breast Cancer. 2020;23:115.

Article  PubMed  PubMed Central  Google Scholar 

Larsen NB, Rasmussen M, Rasmussen LJ. Nuclear and mitochondrial DNA repair: similar pathways? Mitochondrion. 2005;5:89–108.

Article  CAS  PubMed  Google Scholar 

Perkhofer L, Gout J, Roger E, de Almeida FK, Simões CB, Wiesmüller L, Seufferlein T, Kleger A. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut. 2021;70(3):606–17.

Article  CAS  PubMed  Google Scholar 

Azim HA, Loutfy SA, Azim HA Jr, Kamal NS, Abdel Fattah NF, Elberry MH, Abdelaziz MR, Abdelsalam M, Aziz M, Shohdy KS, Kassem L. The landscape of BRCA mutations among egyptian women with breast cancer. Oncol Ther. 2023;15:1–8.

Google Scholar 

Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, et al. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer. 2021;146:30–47.

Article  CAS  PubMed  Google Scholar 

Kwong A, Chen J, Shin VY, Ho JC, Law FB, Au CH, Chan TL, Ma ES, Ford JM. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer. Cancer Genet. 2015;208(9):448–54.

Article  CAS  PubMed  Google Scholar 

Sullivan MR, Bernstein KA. RAD-ical new insights into RAD51 regulation. Genes (Basel). 2018;9(12):629.

Article  PubMed  Google Scholar 

Qin Z, Li J, Tam B, Sinha S, Zhao B, Bhaskaran SP, Huang T, Wu X, Chian JS, Guo M, Kou SH, Lei H, Zhang L, Wang X, Lagniton PNP, Xiao F, Jiang X, Wang SM. Ethnic-specificity, evolution origin and deleteriousness of Asian BRCA variation revealed by over 7500 BRCA variants derived from Asian population. Int J Cancer. 2023;152(6):1159–73.

Article  CAS  PubMed  Google Scholar 

Kwong A, Ho CYS, Shin VY, Au CH, Luk WP, Fung LH, Chan TL, Chan KKL, Ngan HYS, Ma ESK. Germline mutations in Chinese ovarian cancer with or without breast cancer. Mol Genet Genomic Med. 2022;10(7): e1940.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caleca L, Radice P. Refinement of the assignment to the ACMG/AMP BS3 and PS3 criteria of eight BRCA1 variants of uncertain significance by integrating available functional data with protein interaction assays. Front Oncol. 2023;13:1146604.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cetin B, Wabl CA, Gumusay O. The DNA damaging revolution. Crit Rev Oncol Hematol. 2020;156: 103117.

Article  PubMed  Google Scholar 

Ford D, Easton D, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet. 1998;62:676–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rummel S, Varner E, Shriver CD, Ellsworth RE. Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer. Breast Cancer Res Treat. 2013;137:119–25.

Article  PubMed  Google Scholar 

Ellsworth DL, Turner CE, Ellsworth RE. A review of the hereditary component of triple negative breast cancer: High-and moderate-penetrance breast cancer genes, low-penetrance loci, and the role of nontraditional genetic elements. J Oncol. 2019;25:78–96.

Google Scholar 

Melki R, Melloul M, Aissaoui S, El-Harroudi T. Increased prevalence of the founder BRCA1 c. 5309G> T and recurrent BRCA2 c. 1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling. BMC Cancer. 2023;23:339.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdallah N, Purrington KS, Tatineni S, Assad H, Petrucelli N, Simon MS. Racial and ethnic variation in BRCA1 and BRCA2 genetic test results among individuals referred for genetic counseling at a large urban comprehensive cancer center. Cancer Causes Control. 2023;34:141–9.

Article  PubMed  Google Scholar 

Forbes C, Fayter D, de Kock S, Quek RG. A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer. Cancer Manage Res. 2019;15:2321–37.

Article  Google Scholar 

Maqbool M, Bekele F, Fekadu G. Treatment strategies against triple-negative breast cancer: an updated review. Breast Cancer. 2022;15:15–24.

Google Scholar 

Wang J, Zhao H, Ye L, Li J, Zhang H, Zhang C, et al., Diagnostic and prognostic nomograms for lung metastasis in triple-negative breast cancer. Comput Math Methods Med. 2022

Dieci MV, Del Mastro L, Cinquini M, Montemurro F, Biganzoli L, Cortesi L, et al. Inclusion of platinum agents in neoadjuvant chemotherapy regimens for triple-negative breast cancer patients: development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) recommendation by the Italian Association of Medical Oncology (AIOM). Cancers. 2019;11:1137.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Showimi M, Al-Yousef N, Alharbi W, Alkhezayem S, Almalik O, Alhusaini H, et al. MicroRNA-126 expression in the peripheral white blood cells of patients with breast and ovarian cancer is a potential biomarker for the early prediction of cancer risk in the carriers of methylated BRCA1. Oncol Lett. 2022;24:1–9.

Article  Google Scholar 

Biswas T, Efird JT, Prasad S, Jindal C, Walker PR. The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer. Oncotarget. 2017;8: 112712.

Article  PubMed  PubMed Central